nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2026, 05, v.67 477-481
王晞星从“五脏致咳”辨治免疫检查点抑制剂相关性肺炎经验
基金项目(Foundation): 国家中医药管理局国医大师传承工作室建设项目(国中医药办人教函[2022]245号); 山西省中医药管理局科研课题计划(2023ZYYC007)
邮箱(Email): lyfty@163.com;
DOI: 10.13288/j.11-2166/r.2026.05.003
摘要:

总结王晞星教授从“五脏致咳”辨治免疫检查点抑制剂相关性肺炎(CIP)的临证经验。CIP以咳嗽为常见主症,基于“五脏致咳”认为药毒引动癌毒导致五脏失和,进而肺气宣降失常是其核心病机,治疗当调和五脏以恢复肺气正常宣降功能。临证可将CIP分为肺阴亏虚、肺脾两虚兼痰湿、肝火犯肺、肺肾阴虚四种证型,分别拟定柴麦金络润肺汤以滋阴润肺、芪桂培土化饮汤以健脾补肺兼化湿祛痰、柴丹疏郁润金汤以泻肝清肺、地脉金水相生汤以滋肾润肺。

Abstract:

This paper summarizes Professor WANG Xixing's clinical experience in treating immune checkpoint inhibitor-related pneumonitis(CIP) based on the theory of "cough attributed to the five zang (脏) organs". Cough is a common predominant symptom of CIP. According to the theory of "cough attributed to the five zang organs", drug toxicity triggers cancer toxin, leading to disharmony among the five zang organs, and then lung failing to diffuse and govern descent as the core pathogenesis. Therefore, treatment should focus on harmonizing the five zang organs to restore the normal function of lung qi to diffuse and govern descent. In clinical practice, CIP can be classified into four syn‑drome patterns, including lung yin depletion, deficiency of both the lung and the spleen with phlegm-dampness, liver fire harassing the lung, and lung-kidney yin deficiency. Correspondingly, Chaimai Jinluo Runfei Decoction (柴麦金络润肺汤) is used to nourish yin and moisten the lung; Qigui Peitu Huayin Decoction (芪桂培土化饮汤) is used to fortify the spleen and tonify the lung, resolve dampness and dispel phlegm; Chaidan Shuyu Runjin Decoction (柴丹疏郁润金汤) is used to drain liver and clear the lung; and Dimai Jinshui Xiangsheng Decoction (地脉金水相生汤) is used to nourish the kidney and moisten the lung.

参考文献

[1]祁宇飞,任帅,孙银萍.免疫检查点抑制剂相关性肺炎的发病机制及预测标志物的研究进展[J].临床肿瘤学杂志,2024,29(6):612-616.

[2]ALTAN M, SOTO F, ZHONG LL, et al. Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer:a single center experience[J]. Oncologist, 2023,28(11):e1065-e1074.

[3]谢虹,王俊.免疫检查点抑制剂相关不良反应的预测和诊断[J].中国肿瘤生物治疗杂志,2025,32(8):793-798.

[4]张艳琳,李伟,刘丹.免疫检查点抑制剂相关性肺炎的研究进展[J].中国医药,2023,18(3):443-447.

[5]夏琪琪,尹悦,陈博,等.中医药防治免疫检查点抑制剂相关不良反应研究进展[J].中医临床研究,2025,17(29):7-14.

[6]邱悦,马雪,梁路,等.免疫检查点抑制剂相关肺炎的中西医研究现状与分析[J].现代临床医学,2022,48(3):222-225.

[7]程海波.癌毒病机理论探讨[J].中医杂志,2014,55(20):1711-1715.

[8]邵世梁,焦丽静,王怡超,等.从“火与元气不两立”论治恶性肿瘤免疫检查点抑制剂相关皮肤免疫不良反应[J].中医杂志,2025,66(16):1656-1661.

[9]李宜放.王晞星学术思想与临床经验总结及晚期胃癌证治规律研究与生存评价[D].北京:北京中医药大学,2012.

[10]樊燕飞.生脉散加减辅助化疗在气阴两虚证宫颈癌根治术后患者中的应用效果[J].妇儿健康导刊,2023,2(13):48-50.

[11]韩毅,臧红敏,罗艳丽,等.生脉散加减辅助无创机械通气对慢性阻塞性肺疾病急性加重期患者免疫功能、氧化应激损伤的影响[J].河北中医,2022,44(4):564-568,573.

[12]王汉萍,郭潇潇,周佳鑫,等.免疫检查点抑制剂相关肺炎的临床诊治建议[J].中国肺癌杂志,2019,22(10):621-626.

[13]胡炬,梁子成,谭小宁,等.石上柏外泌体样纳米囊泡对肝癌细胞增殖、形态、迁移、侵袭、凋亡的影响[J].现代肿瘤医学,2024,32(16):2937-2944.

[14]顾逸飞,徐子金,王平.基于网络药理学、分子对接和实验验证的三叶青治疗肝细胞癌作用机制研究[J].中国中医药信息杂志,2024,31(11):51-59.

基本信息:

DOI:10.13288/j.11-2166/r.2026.05.003

中图分类号:R249;R259

引用信息:

[1]祁雪,杨晞,王馨悦,等.王晞星从“五脏致咳”辨治免疫检查点抑制剂相关性肺炎经验[J].中医杂志,2026,67(05):477-481.DOI:10.13288/j.11-2166/r.2026.05.003.

基金信息:

国家中医药管理局国医大师传承工作室建设项目(国中医药办人教函[2022]245号); 山西省中医药管理局科研课题计划(2023ZYYC007)

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文